Rutgers Cancer Institute in conjunction with Robert Wood Johnson University Hospital New Brunswick, an RWJBarnabas Health facility, are now offering CAR T-cell therapy for forms of B-cell lymphoma. Learn more about this ‘living drug.’
Investigators at Rutgers Cancer Institute of New Jersey have determined that an overabundance of a novel gene known as ADNP in an aggressive form of ovarian cancer may serve as a prognostic tool. Read more
A drastic, unexplained change in health had Ruth Hansen seeking answers. When diagnosed with a condition known as Cushing’s syndrome, she found expertise in the care of this rare tumor type at Rutgers Cancer Institute and RWJBarnabas Health.
Read more
Visit our Cancer Prevention Resource Center for more information about cancer screening. Learn more
A multi-center clinical trial led by Rutgers Cancer Institute and Dr. Salma Jabbour finds that adding immunotherapy to standard treatment for a form of lung cancer is safe and tolerable as a first-line therapy. Results are published in the journal ‘JAMA Oncology.’ Learn more
Steve K. Libutti, MD, FACS, was awarded a $1.2 million ‘Petersen Accelerator Award’ from the Neuroendocrine Tumor Research Foundation to pursue work leading to precise treatments for neuroendocrine tumors – an uncommon cancer impacting an estimated 171,000 Americans. Learn more
Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903-2681
732-235-CINJ (2465)
Patient Care
From doctor to nurse to social worker and others, our comprehensive team guides both patient and family through their cancer journey. Learn more
Clinical Trials
As one of the National Cancer Institute’s designated cancer centers, the Rutgers Cancer Institute of New Jersey provides access to the latest medicines through clinical trials.
Learn more
Research
Cancer research is one of the pillars of the Cancer Institute of New Jersey. Our physician-scientists engage in innovative techniques to unlock the mysteries of cancer, helping to make unique advances in the field.
Addition of Immunotherapy to Standard Treatment for Advanced Stage Non-Small Cell Lung Cancer is Safe and Tolerable as First-Line Therapy
Learn more
$1.2 Million Awarded to Rutgers Cancer Institute Director to Accelerate Neuroendocrine Tumor Research
Learn more
Novel Cell-Based Therapy Induces Cell Death in Sensitive and Resistant Non-Hodgkin Lymphoma Models
Learn more
Analysis of Different Treatment Strategies for Non-Invasive Breast Cancer Shows Radiation Treatment Alone is Cost-Effective
Learn more
Retrospective Analysis Shows Proton Therapy Well Tolerated in Patients Undergoing Breast Conserving Surgery
Learn more
Deep DNA sequencing analysis conducted by Rutgers Cancer Institute of New Jersey investigators examining genomic differences within tumors for prediction of disease relapse in certain hematologic malignancies has identified small mutations. Learn more
Rutgers Cancer Institute Researchers Identify Novel Gene Associated with Prognosis in Aggressive form of Ovarian Cancer
Learn more
Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903-2681
732-235-CINJ (2465)
Copyright ©2020 Rutgers, The State University of New Jersey, all rights reserved | Privacy Policy
Rutgers Cancer Institute of New Jersey is the state's only National Cancer Institute-designated Comprehensive Cancer Center
The information contained in this website is not a substitute for medical consultation. A physician should always be consulted for any health problem or medical condition.
